Search

Your search keyword '"MEMOLI B"' showing total 213 results
Start Over Author "MEMOLI B"
213 results on '"MEMOLI B"'

10. Inflammation may modulate interleukin 6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor

Author

MEMOLI B, PROCINO A, ESPOSITO P, GRANDALIANO G, PERTOSA G, DEL PRETE MA, ANDREUCCI M, DILILLO S, FERULANO G, CILLO C, SAVASTANO S, COLAO A, GUIDA B., CALABRO', Paolo, Memoli, B, Procino, A, Calabro', Paolo, Esposito, P, Grandaliano, G, Pertosa, G, DEL PRETE, Ma, Andreucci, M, Dilillo, S, Ferulano, G, Cillo, C, Savastano, S, Colao, A, and Guida, B.

Published
2007

11. 'In vivo' modulation of solubile antagonistic IL-6 receptor and release in ESRD

Author

Memoli B., Grandaliano G., Soccio M., Guida B., Bisesti V., Esposito P., Procino A., Marrone D., Michael A., Andreucci M., Schena F. P., Pertosa G., POSTIGLIONE, LOREDANA, Memoli, B., Grandaliano, G., Soccio, M., Postiglione, Loredana, Guida, B., Bisesti, V., Esposito, P., Procino, A., Marrone, D., Michael, A., Andreucci, M., Schena, F. P., and Pertosa, G.

Abstract

Soluble gp130 (sgp130) is a soluble circulating receptor of IL-6 with "antagonistic" biologic activity. It is generated independently by either shedding of the extracellular domain of membrane gp130 or alternative mRNA splicing. This study was addressed to clarify the mechanisms underlying sgp130 synthesis and release in patients who undergo regular dialysis treatment (RDT) using dialytic membranes with different biocompatibility. Two groups of RDT patients were enrolled: 11 patients who were treated with cellulosic membranes (C) and 10 patients who were treated with synthetic membranes (S). Ten healthy subjects constituted the control group. Serum samples and peripheral blood mononuclear cells (PBMC) were harvested in all groups (before dialysis in RDT patients). PBMC were cultured for 24 h in the absence or presence of LPS. The serum levels of sgp130 were significantly higher in C group than in control and S patients (C, 603.1 +/- 89.9; control, 396 +/- 49.5; S, 423.4 +/- 27.7 ng/ml; P < 0.01). PBMC from C patients, in the absence of any mitogenic stimulation, released a significantly greater amount of sgp130 as compared with S and control groups (C, 532.6 +/- 161.2; S, 332.4 +/- 148.6; control, 341.4 +/- 125.4 pg/ml; P < 0.01). The sgp130 release was positively correlated with the release of both IL-6 (r = 0.336, P < 0.05) and sIL-6R receptor (r = 0.324, P < 0.05). A significantly higher gp130 gene expression was also observed in unstimulated PBMC from C patients when compared with control and S groups. It is interesting that the expression of the 85-bp exon characteristic of the alternative splicing mRNA for sgp130 was low in all groups. Finally, confocal microscopy analysis showed an increased expression of gp130 on cell surface in unstimulated PBMC from C patients as compared with control and S groups. Our results demonstrate that in patients on RDT with C membranes, the synthesis and release of sgp130 "antagonistic" receptor is significantly increased. This release is seemingly due to a shedding of membrane-bound gp130 receptor. The increased sgp130 release may partially counteract the inflammatory effects caused by IL-6.

Published
2005

14. [Predictive and diagnostic factors of malnutrition in hemodialysis patients]

Author

MEMOLI B, GUIDA, BRUNA, SARAVO MT, NASTASI A, TRIO R, LIBERTI R, D'ARCANGELO R, ROMANO G, ESPOSITO A, CIANCIARUSO B., Memoli, B, Guida, Bruna, Saravo, Mt, Nastasi, A, Trio, R, Liberti, R, D'Arcangelo, R, Romano, G, Esposito, A, and Cianciaruso, B.

Subjects
Inflammation, Male, Parathyroidectomy, Muscle Proteins, Middle Aged, Combined Modality Therapy, Kidney Transplantation, Hemodialysis Solutions, Nutrition Disorders, C-Reactive Protein, Liver, Cardiovascular Diseases, Renal Dialysis, Risk Factors, Diet, Protein-Restricted, Electric Impedance, Cytokines, Humans, Kidney Failure, Chronic, Biomarkers, Acute-Phase Proteins
Abstract

The relationship between malnutrition and inflammation is by now well established. IL-6 and, probably, other proinflammatory cytokines (mainly IL-1 and TNF) may represent the link between these two entities since these interleukins may promote loss of appetite, muscle protein breakdown and reduced hepatic synthesis of "negative" acute phase proteins like albumin, prealbumin and transferrin. IL-6 also stimulates up to 1000 fold the hepatic synthesis of "positive" acute phase proteins, mainly C-reactive Protein (CRP) and Serum Amyloid A. The association between CRP and cardiovascular mortality in the general population, as well as in haemodialysed uraemic patients, is well established. These crucial interrelationships have modified the interpretation of serum albumin concentration in the diagnosis of malnutrition; a reduced serum albumin concentration, in fact, in the presence of high CRP values should point towards a diagnosis of inflammation, though the inflammation may often induce weight loss or a condition of malnutrition. After switching most patients to a more biocompatible dialysis membrane and improvement of the quality of the dialysis fluid (by adopting hydrophobic filters at the water entry of dialysis devices and bicarbonate powder cartridges) nephrologists have focused their attention on other sources of inflammation (e.g. artificial vascular protheses, presence of infected thrombi, Clamidiae, Helicobacter Pilori, dental granulomas etc.). Starting from these assumptions the diagnosis of malnutrition, once focused mainly on serum albumin reduction, must be based on other parameters (clinical history of body mass wasting, dietary and anthropometric assessment, subjective global assessment, bioimpedance analysis etc.). All these investigations, however, must be examined together to obtain suitable information on the risk of malnutrition in dialysis patients. A comprehensive approach to malnutrition-inflammation in dialysis patients is the object of the present nephrology conference.

Published
2002

15. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes

Author

MEMOLI B, BISESTI V, POSTIGLIONE L, CONTI A, MARZANO L, CAPUANO A, ANDREUCCI M, BALLETTA MM, GUIDA B, TETTA C, COLLABORATIVE STUDY GROUP ON SMC MEMBRANE, MINUTOLO, Roberto, Memoli, B, Minutolo, Roberto, Bisesti, V, Postiglione, L, Conti, A, Marzano, L, Capuano, A, Andreucci, M, Balletta, Mm, Guida, B, Tetta, C, COLLABORATIVE STUDY GROUP ON SMC, Membrane, B., Memoli, Minutolo, R., Bisesti, V., Postiglione, Loredana, Conti, A., Marzano, L., Capuano, A., Andreucci, M., Balletta, M., Guida, B., and Tetta, C.

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, Serum albumin, Biocompatible Materials, Peripheral blood mononuclear cell, Renal Dialysis, Internal medicine, Blood plasma, medicine, Humans, Cellulose, Complement Activation, Dialysis, Serum Albumin, Cross-Over Studies, biology, business.industry, Interleukin-6, C-reactive protein, Albumin, Membranes, Artificial, Middle Aged, Complement system, Nutrition Disorders, Endocrinology, Cytokine, C-Reactive Protein, Nephrology, Immunology, biology.protein, Leukocytes, Mononuclear, Female, business
Abstract

Protein malnutrition, a condition associated with an albumin concentration less than 3.5 g/dL, has been shown to be a major risk factor for increased mortality in hemodialysis patients. The aim of this cross-over study was to evaluate the relationship between the type of membrane adopted and serum albumin changes by measuring peripheral blood mononuclear cells (PBMC) interleukin-6 (IL-6) release, serum albumin, and plasma concentrations of C-reactive protein (CRP) in 18 patients dialyzed with different membranes. During the study, all patients were dialyzed with cuprophan (CU), synthetically modified cellulosic (SMC) membrane (a new cellulosic membrane with lesser complement activation), and cellulose diacetate (CD) membrane, and have served as their own controls. IL-6 spontaneous release by PBMC resulted after 3 months of SMC (436.2 +/- 47.4 pg/mL) significantly (P < 0.05) reduced as compared with CU (569.3 +/- 24.5 pg/mL). This effect was more evident after 6 months of dialysis with SMC (220 +/- 35.3 pg/mL, P < 0.01 versus CU and versus 3 months of SMC). The passage to CD membrane was followed by a progressive new increase in the IL-6 PBMC release (332.3 +/- 30.7 after 3 months, and 351.2 +/- 35.8 pg/mL after 6 months, respectively) that, however, remained significantly (P < 0.05) lower than CU. The behavior of CRP plasma levels resembled that of IL-6 PBMC release (23.3 +/- 4.7 in CU, 11.0 +/- 2.1 after 3 months in SMC, and 7.9 +/- 1.5 after 6 months in SMC, respectively). IL-6 release values were positively correlated with circulating levels of CRP (r = 0.3264, P < 0.002). Serum albumin increased after 6 months of dialysis with SMC membranes (3.25 +/- 0.09 g/dL in CU and 3.64 +/- 0.07 g/dL in SMC, P < 0.05). When the patients were switched to CD, serum albumin showed a slight, though not statistically significant, decrease. Serum albumin concentrations negatively correlated with both IL-6 release values (r = -0.247, P < 0.05) and CRP plasma levels (r = -0.433, P < 0.001). In conclusion, our data clearly show that a significant relationship exists between biocompatibility of the membranes and serum albumin changes; serum albumin levels, in fact, are negatively correlated with the PBMC spontaneous IL-6 release values and CRP circulating levels.

Published
2002

16. Collaborative Study Group on SMC Membrane. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes

Author

MEMOLI B, MINUTOLO R, BISESTI V, POSTIGLIONE, LOREDANA, CONTI A, MARZANO L, CAPUANO A, ANDREUCCI M, BALLETTA MM, TETTA C., GUIDA, BRUNA, Memoli, B, Minutolo, R, Bisesti, V, Postiglione, Loredana, Conti, A, Marzano, L, Capuano, A, Andreucci, M, Balletta, Mm, Guida, Bruna, and Tetta, C.

Published
2002

22. Hepatocellular functions of human liver cells in oxygen-permeable membrane device

Author

De Bartolo L., Salerno S., Morelli S., Giorno L., Rende M., Memoli B., Andreucci, V.E., Bader, Drioli, Loredana De, Bartolo, Simona, Salerno, Sabrina, Morelli, Lidietta, Giorno, Maria, Rende, Memoli, Bruno, Vittorio Emanuele, Andreucci, Augustinus, Bader, and Enrico, Drioli

Subjects
Human liver, Mechanical Engineering, General Chemical Engineering, chemistry.chemical_element, General Chemistry, Membrane bioreactor, Oxygen, hepatocellular functions, chemistry, Immunology, Bioreactor, Biophysics, General Materials Science, Semipermeable membrane, oxygen-permeable membrane bioreactor, Water Science and Technology
Abstract

In recent years numerous bioreactor hepatocytedevices using different materials and configura-tions have been developed and most attempts werefocused on adapting bioreactor technologies to theculture of primary hepatocytes. An oxygen perme-able membrane bioreactor based on the design byBader et al. [1–2] reconstructing the liver platearchitecture but with different configuration andutilizing human hepatocytes was assessed in thisstudy. In this device, human hepatocytes were cul-tured between flat-sheet gas-permeable polymericmembranes, which (1) ensure the diffusion of O

Published
2006

28. Loop diuretics and renal vasodilators in acute renal failure

Author

Memoli B, Libetta C, Andreucci VE, CONTE, Giuseppe, Memoli, Bruno, Libetta, C, Conte, G, Andreucci, Ve, Memoli, B, and Conte, Giuseppe

Subjects
Dopamine, Vasodilator Agents, Loop of Henle, Animals, Humans, Acute Kidney Injury, Diuretics, Glomerular Filtration Rate, Renal Circulation, Renal Plasma Flow, Effective
Abstract

Loop diuretics are powerful drugs able to increase urinary sodium and water excretion even in conditions of marked impairment of renal function. Loop diuretics are useful in preventing or ameliorating the course of acute renal failure. This effect may be obtained when they are used within 18 h after the ischaemic and/or toxic event. Loop diuretics reduce tubular work, providing resistance to cellular ischaemia. Other important beneficial effects include tubular wash-out of cellular debris and inhibition of tubuloglomerular feedback. Among vasodilators, dopamine, when used at 'dopaminergic dosage' is useful in preventing acute renal failure. Its efficacy is demonstrated in several situations of renal hypoperfusion, i.e. salt depletion, cyclosporin administration, and therapy with recombinant interleukin 2 in cancer patients. According to our studies it appears that dopamine should be used in the early phases of acute renal failure to improve renal perfusion, re-establish glomerular filtration rate, and increase tubular flow.

Published
1994

32. Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial

Author

Locatelli, F., primary, Altieri, P., additional, Andrulli, S., additional, Sau, G., additional, Bolasco, P., additional, Pedrini, L. A., additional, Basile, C., additional, David, S., additional, Gazzanelli, L., additional, Tampieri, G., additional, Isola, E., additional, Marzolla, O., additional, Memoli, B., additional, Ganadu, M., additional, Reina, E., additional, Bertoli, S., additional, Ferrara, R., additional, Casu, D., additional, Logias, F., additional, Tarchini, R., additional, Mattana, G., additional, Passaghe, M., additional, Fundoni, G., additional, Villa, G., additional, Di Iorio, B. R., additional, Pontoriero, G., additional, and Zoccali, C., additional

Published
2014
Full Text
View/download PDF

34. Cytokine production in haemodialysis

Author

Memoli B and Memoli, Bruno

Subjects
business.industry, medicine.medical_treatment, Monocyte, Interleukin, Hematology, General Medicine, medicine.disease, Peripheral blood mononuclear cell, Cytokine, medicine.anatomical_structure, Immune system, Nephrology, Renal Dialysis, Immunology, medicine, Cytokines, Humans, Tumor necrosis factor alpha, business, Dialysis, Immunodeficiency
Abstract

Many aspects regarding morbidity and mortality of dialysis patients are related to the production of cytokines by peripheral blood mononuclear cells. Clinical alterations resulting from cytokine production and release may include dialysis amyloidosis, malnutrition and atherogenesis. Cytokine release may also play a relevant role in immunodeficiency of dialysis patients by inducing alterations in immune and host-defense system. Interleukin-1, interleukin-6 and tumor necrosis factor are three pro-inflammatory cytokines, mainly produced by monocytes, and involved in pathogenetic aspects of hemodialysis-related diseases. In this review we analyse the mechanisms underlying monocyte activation and describe the different modalities for studying cytokine production and release. Clinical implications of cytokine production are also discussed.

Published
1999

35. Anaemia in CKD 1-5

Author

Hirata, M., primary, Tashiro, Y., additional, Aizawa, K., additional, Endo, K., additional, Hirata, M., additional, Serizawa, K., additional, Yogo, K., additional, Cases, A., additional, Portoles, J., additional, Calls, J., additional, Martinez-Castelao, A., additional, Munar, M. A., additional, Segarra, A., additional, Samouilidou, E., additional, Pantelias, K., additional, Petras, D., additional, Mpakirtzi, T., additional, Pipili, C., additional, Chatzivasileiou, G., additional, Vasiliou, K., additional, Denda, E., additional, Grapsa, E., additional, Tzanatos, H., additional, Shoji, S., additional, Inaba, M., additional, Tomosugi, N., additional, Okuno, S., additional, Ichii, M., additional, Yamakawa, T., additional, Kurihara, S., additional, Barsan, L., additional, Stanciu, A., additional, Stancu, S., additional, Capusa, C., additional, Bratescu, L., additional, Mircescu, G., additional, Kuo, K.-L., additional, Hung, S.-C., additional, Lee, T.-S., additional, Tarng, D.-C., additional, Nistor, I., additional, Covic, A., additional, Goldsmith, D., additional, Garrido, P., additional, Fernandes, J., additional, Ribeiro, S., additional, Vala, H., additional, Parada, B., additional, Alves, R., additional, Belo, L., additional, Costa, E., additional, Santos-Silva, A., additional, Reis, F., additional, Abdulnabi, K., additional, Ullah, A., additional, Abdulateef, A., additional, Howse, M., additional, Khalil, A., additional, Fouqueray, B., additional, Hoffmann, M., additional, Addison, J., additional, Manamley, N., additional, Stamopoulos, D., additional, Mpakirtzi, N., additional, Afentakis, N., additional, Yu, K.- H., additional, Chou, J., additional, Klaus, S., additional, Schaddelee, M., additional, Kashiwa, M., additional, Takada, A., additional, Neff, T., additional, Galle, J., additional, Claes, K., additional, Di Giulio, S., additional, Guerin, A., additional, Herlitz, H., additional, Kiss, I., additional, Wirnsberger, G., additional, Froissart, M., additional, Winearls, C., additional, Martinez Castelao, A., additional, Cases Amenos, A., additional, Torre Carballada, A., additional, Torralba Iranzo, F. J., additional, Bronsoms Artero, J. M., additional, Toran Monserrat, D., additional, Valles Prats, M., additional, Merino, J. L., additional, Espejo, B., additional, Bueno, B., additional, Amezquita, Y., additional, Paraiso, V., additional, Kiss, Z., additional, Kerkovits, L., additional, Ambrus, C., additional, Kulcsar, I., additional, Szegedi, J., additional, Benke, A., additional, Borbas, B., additional, Ferenczi, S., additional, Hengsperger, M., additional, Kazup, S., additional, Nagy, L., additional, Nemeth, J., additional, Rozinka, A., additional, Szabo, T., additional, Szelestei, T., additional, Toth, E., additional, Varga, G., additional, Wagner, G., additional, Zakar, G., additional, Gergely, L., additional, Exarchou, K., additional, Tanahill, N., additional, Anthoney, A., additional, Ahmed, S., additional, Oprican, R., additional, Lipan, M., additional, Chirculescu, B., additional, Roger, S., additional, Malecki, R., additional, Farouk, M., additional, Dellanna, F., additional, Thomas, M., additional, Touam, M., additional, Chantrel, F., additional, Bouiller, M., additional, Hurot, J.-M., additional, Raphael, T., additional, Testa, A., additional, Veillon, S., additional, Vendrely, B., additional, Masoumi, Z., additional, Ahmadpoor, P., additional, Ghaderian, S. M. H., additional, Nafar, M., additional, Samavat, S., additional, Samadian, F., additional, Poorrezagholi, F., additional, Shahidi, M., additional, Riccio, E., additional, Visciano, B., additional, Capuano, I., additional, Memoli, A., additional, Mozzillo, G., additional, Memoli, B., additional, and Pisani, A., additional

Published
2013
Full Text
View/download PDF

37. Transplantation - clinical II

Author

Riegersperger, M., primary, Plischke, M., additional, Steiner-Boker, S., additional, Seidinger, D., additional, Winkelmayer, W., additional, Sunder-Plassmann, G., additional, Vlahovic, P., additional, Cvetkovic, T., additional, Djordjevic, V., additional, Velickovic-Radovanovic, R., additional, Stefanovic, N., additional, Ignjatovic, A., additional, Sladojevic, N., additional, Cademartori, V., additional, Massarino, F., additional, Parodi, E. L., additional, Russo, R., additional, Sofia, A., additional, Fontana, I., additional, Viviani, G. L., additional, Garibotto, G., additional, Mai, M., additional, Mai, W., additional, Taner, B., additional, Wadei, H., additional, Prendergast, M., additional, Gonwa, T., additional, Martin, J., additional, Aurore, S., additional, Aline, C. S., additional, Nicolas, M., additional, Manolie, M., additional, Catherine, S., additional, Eric, A., additional, Christophe, M., additional, Brakemeier, S., additional, Liefeldt, L., additional, Glander, P., additional, Waiser, J., additional, Lachmann, N., additional, Schonemann, C., additional, Zukunft, B., additional, Illigens, P., additional, Schmidt, D., additional, Wu, K., additional, Rudolph, B., additional, Neumayer, H.-H., additional, Budde, K., additional, Pallardo Mateu, L., additional, Gavela Martinez, E., additional, Sancho Calabuig, A., additional, Crespo Albiach, J., additional, Beltran Catalan, S., additional, Kanter Berga, J., additional, Kimura, T., additional, Yagisawa, T., additional, Ishikawa, N., additional, Sakuma, Y., additional, Hujiwara, T., additional, Nukui, A., additional, Yashi, M., additional, Duraes, J., additional, Malheiro, J., additional, Fonseca, I., additional, Rocha, A., additional, Martins, L. S., additional, Almeida, M., additional, Dias, L., additional, Castro-Henriques, A., additional, Cabrita, A., additional, Volpe, A., additional, Quaglia, M., additional, Menegotto, A., additional, Fenoglio, R., additional, Izzo, C., additional, Airoldi, A., additional, Terrone, C., additional, Stratta, P., additional, Ahmed, B., additional, Mireille, K., additional, Nilufer, B., additional, Annick, M., additional, Karl Martin, W., additional, Anh-Dung, H., additional, Dimitri, M., additional, Philippe, M., additional, Judith, R., additional, Daniel, A., additional, Lan, Y., additional, Heine, C., additional, Capone, V., additional, Grace, B., additional, Clayton, P., additional, Cass, A., additional, Mcdonald, S., additional, Fujiwara, T., additional, Iwabuchi, T., additional, Muraishi, O., additional, Torregrosa, V., additional, Barros, X., additional, Martinez de Osaba, M. J., additional, Paschoalin, R., additional, Campistol, J. M., additional, Hassan, R., additional, El-Hefnawy, A., additional, Soliman, S., additional, Shokeir, A., additional, Cobanoglu Kudu, A., additional, Gungor, O., additional, Kircelli, F., additional, Altinel, E., additional, Asci, G., additional, Ozbek, S. S., additional, Toz, H., additional, Ok, E., additional, Sandrini, S., additional, Setti, G., additional, Valerio, F., additional, Possenti, S., additional, Torrisi, I., additional, Polanco, N., additional, Garcia-Puente, L., additional, Gonzalez Monte, E., additional, Morales, E., additional, Gutierrez, E., additional, Bengoa, I., additional, Hernandez, A., additional, Caballero, J., additional, Morales, J. M., additional, Andres, A., additional, Sgarlato, V., additional, Comai, G., additional, La Manna, G., additional, Moretti, I., additional, Grandinetti, V., additional, Martelli, D., additional, Scolari, M. P., additional, Stefoni, S., additional, Valentini, C., additional, Persici, E., additional, Cappuccilli, M. L., additional, Liviano D'arcangelo, G., additional, Fabbrizio, B., additional, Carretta, E., additional, Mosconi, G., additional, Feliciangeli, G., additional, Grigioni, F. W., additional, Apicella, L., additional, Guida, B., additional, Vitale, S., additional, Garofalo, G., additional, Russo, L., additional, Maresca, I., additional, Rossano, R., additional, Memoli, B., additional, Carrano, R., additional, Federico, S., additional, Sabbatini, M., additional, Carta, P., additional, Zanazzi, M., additional, DI Maria, L., additional, Caroti, L., additional, Miejshtri, A., additional, Tsalouchos, A., additional, Bertoni, E., additional, Sezer, S., additional, Erkmen Uyar, M., additional, Colak, T., additional, Bal, Z., additional, Tutal, E., additional, Kalaci, G., additional, Ozdemir Acar, F. N., additional, Jacquelinet, C., additional, Bayat, S., additional, Pernin, V., additional, Portales, P., additional, Szwarc, I., additional, Garrigue, V., additional, Vetromile, F., additional, Delmas, S., additional, Eliaou, J. F., additional, Mourad, G., additional, Huber, L., additional, Slowinski, T., additional, Naik, M., additional, Nakai, K., additional, Fujii, H., additional, Kono, K., additional, Goto, S., additional, Ishimura, T., additional, Takeda, M., additional, Fujisawa, M., additional, Nishi, S., additional, Pereira Paschoalin, R., additional, Torregrosa, J. V., additional, Barros Freiria, X., additional, Duran Rebolledo, C. E., additional, Sanchez Escuredo, A., additional, Sole, M., additional, Youssouf, S., additional, Tabbasm, F., additional, Bell, R., additional, Al-Jayyousi, R., additional, Warwick, G., additional, Grall, A., additional, Treguer, L., additional, Essig, M., additional, Lecaque, C., additional, Noel, N., additional, Buchler, M., additional, Bertrand, D., additional, Rivalan, J., additional, Braun, L., additional, Villemain, F., additional, Hurault de Ligny, B., additional, Totet, A., additional, Pestourie, N., additional, Toubas, D., additional, Nevez, G., additional, Le Meur, Y., additional, Nour el Houda, B., additional, Mustapha, H., additional, Wafaa, F., additional, Inass, L., additional, Rambabova Bushljetikj, I., additional, Masin-Spasovska, J., additional, Spasovski, G., additional, Popov, Z., additional, Sikole, A., additional, Ivanovski, N., additional, Raimundo, M., additional, Guerra, J., additional, Teixeira, C., additional, Santana, A., additional, Silva, S., additional, Mil Homens, C., additional, Gomes Da Costa, A., additional, Loredo, D., additional, Cleres, M., additional, Gondolesi, G., additional, Gutierrez, L. M., additional, Fortunato, R. M., additional, Descalzi, V., additional, and Raffaele, P., additional

Published
2012
Full Text
View/download PDF

40. Interleukin-6 production induced in peripheral blood mononuclear cells by a serum factor from IgA nephropathy patients is inhibited in vitro by specific sugars

Author

Rampino, T., Libetta, C., Giuseppe Palumbo, Memoli, B., Dal Canton, A., Rampino, T, Libetta, C, Palumbo, Giuseppe, Memoli, Bruno, and Dal Canton, A.

Subjects
Biological Factors, Interleukin-6, Monosaccharides, Leukocytes, Mononuclear, Humans, Glomerulonephritis, IGA, Blood Proteins, Cells, Cultured
Abstract

The basal production of IL-6 by cultured peripheral blood mononuclear cells (PBMC) from patients with IgAN, is markedly higher (A, 109 pg/ml) as compared to that of PBMC of either patients without clinical signs (I, 39 pg/ml) or appropriate controls (C, 44 pg/ml). When PBMC from healthy subjects were incubated in the presence of sera from patients A, the IL-6 production was strongly enhanced. No such an effect was observed by stimulating PBMC with sera from the other two groups of subjects (I, C). In another experiment we observed that the IL-6 production stimulated by serum from patients A could be inhibited by addition of specific monosaccharides. The inhibitory effect was rapidly abolished when the sugar-containing medium was substituted with the original one. Finally molecular components from serum of A were grossly separated by gel column chromatography. Individual fractions were incubated with PBMC of C: fractions with Mr30,000 highly stimulated the release of IL-6 (up to 1320 pg/ml); fractions with lower molecular weight were inactive. The data suggest the presence of an IL-6 releasing factor in the serum of IgAN patients. Although the chemical nature of such a factor is not yet established, the observations reported focus our attention to the lectins family. Since this factor seems potentially important in the understanding of the pathogenesis of IgAN, both its isolation and structural/functional characterization deserve further efforts.

Published
1994

45. Interleukin-6 production of uraemic haemodialysed patients: effects of different membranes

Author

Memoli, B., Libetta, C., Rampino, T., Simone, W., Meccariello, S., Stangerlin, P., ANTONIO DAL CANTON, Andreucci, V. E., Memoli, Bruno, Libetta, C, Rampino, T, De Simone, W, Meccariello, S, Stangherlin, P, Dal Canton, A, and Andreucci, Ve

Subjects
Male, Interleukin-6, Renal Dialysis, Humans, Methylmethacrylates, Female, Membranes, Artificial, Middle Aged, Cellulose, Aged, Uremia
Abstract

Interleukin-6 (Il-6) has a complex spectrum of biological activities (growth and differentiation of B cells and synthesis of acute-phase proteins by liver). To evaluate the role of this cytokine in the inflammatory response induced by blood interaction with haemodialysis membranes, we have investigated Il-6 synthesis and release in supernatant of 24-h cultured peripheral blood mononuclear cells (PBMC) isolated from ten haemodialysed patients and eight healthy control subjects. In haemodialysed patients, blood samples were drawn before and after their usual dialytic treatment with cuprophane membranes and following 1 and 2 months with polymethylmethacrylate (PMMA) membranes. Il-6 was determined by 72-h incubation of serial dilutions of PBMC supernatant with Il-6-dependent cell line 7TD1; dilutions of rIl-6 were included as standard. Compared to Il-6 synthesis in control subjects (3.3 +/- 2.8 U/ml) the patients usually haemodialysed with cuprophane membranes showed significantly greater values (9.8 +/- 4.5 U/ml, P less than 0.02 before the treatment, and 10.4 +/- 6.1 U/ml, P less than 0.05 after the treatment). A significant reduction, in comparison with the values obtained with cuprophane membranes, was obtained after 1 month (5.3 +/- 2 U/ml, P less than 0.02 before the treatment, and 7.5 +/- 6 U/ml after the treatment) and especially after 2 months (3.4 +/- 3.2 U/ml, P less than 0.02 before the treatment, and 4.4 +/- 3.4 U/ml, P less than 0.05 after the treatment) of dialysis with PMMA membranes. In conclusion, our results show increased Il-6 production in haemodialysed patients usually treated with cuprophane membranes, suggesting a chronic stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Published
1991

46. Human galactosylated membrane bioreactor for the long-term maintenance of liver specific functions

Author

De Bartolo, L., primary, Morelli, S., additional, Lopez, L.C., additional, Giorno, L., additional, Barbieri, G., additional, Salerno, S., additional, Rende, M., additional, Curcio, E., additional, Procino, A., additional, Favia, P., additional, Memoli, B., additional, Andreucci, V.E., additional, d'Agostino, R., additional, and Drioli, E., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results